Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB/IIA, Single-centered Study of the Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasia

NCT02528526 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT02528526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02528526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB/IIA, Single-centered Study of the Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasia
Lead sponsor
University of Zurich
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 28, 2014
Completion date
December 31, 2016
Enrollment
69 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, colorectal neoplasms, hepatocellular cancer, pancreatic neoplasms